
Nov 3, 2026
Fate Therapeutics, Inc. (NASDAQ:FATE) Stock Has Average Target Price of $5.90 According to Analysts
Fate Therapeutics (NASDAQ:FATE) has received an average "Hold" rating from analysts, with a 12-month average target price of $5.90. The company reported a quarterly loss of $0.25 per share and $2.08 million in revenue, remaining unprofitable with a negative net margin. Institutional investors hold a significant 97.54% stake, including recent purchases by BlackRock and Johnson & Johnson.
Company relevance
100.00%
Company sentiment
Neutral
Overall sentiment
Somewhat-Bullish